ロード中...
Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis C Virus Infection
BACKGROUND: The safety of immune checkpoint inhibitors (ICIs) in patients with hepatitis C virus (HCV) infection has not been studied in many cancers, as these patients were excluded from most ICI trials. This poses a degree of uncertainty when a patient with HCV is being considered for ICIs in the...
保存先:
| 出版年: | Oncologist |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley & Sons, Inc.
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8100564/ https://ncbi.nlm.nih.gov/pubmed/33655663 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13739 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|